Meeting
2016 Gastrointestinal Cancers Symposium
Blood neuroendocrine tumor gene cluster analysis to predict somatostatin analog response.
Authors
Mark S. Kidd
Yale School of Medicine, New Haven, CT
Mark S. Kidd , Ignat Drozdov , Irvin Mark Modlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 276)
DOI
10.1200/jco.2016.34.4_suppl.276
Abstract #
276
Poster Bd #
D22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2021 Gastrointestinal Cancers Symposium
Cost of treatment change among patients with neuroendocrine tumors (NET) treated originally with somatostatin analogs.
First Author: Bernard Tawfik
Poster
2018 Gastrointestinal Cancers Symposium
The antidiarrheal efficacy of a proprietary amino acid mixture in gastroenteropancreatic neuroendocrine patients.
First Author: Aman Chauhan
Poster
2015 Gastrointestinal Cancers Symposium
Treatment of neuroendocrine tumors (NETs) with combination of everolimus and lu-177 radiolabeled somatostatin analogue.
First Author: Ali Husain Aljubran